Precision BioSciences, Inc. (DTIL)
NASDAQ: DTIL · Real-Time Price · USD
5.93
+0.04 (0.68%)
Feb 21, 2025, 4:00 PM EST - Market closed
Precision BioSciences Revenue
Precision BioSciences had revenue of $576.00K in the quarter ending September 30, 2024, a decrease of -95.61%. This brings the company's revenue in the last twelve months to $75.10M, up 43.62% year-over-year. In the year 2023, Precision BioSciences had annual revenue of $48.73M with 94.15% growth.
Revenue (ttm)
$75.10M
Revenue Growth
+43.62%
P/S Ratio
0.46
Revenue / Employee
$688,954
Employees
109
Market Cap
45.49M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
DTIL News
- 3 days ago - Precision BioSciences Touts Encouraging Initial Safety And Antiviral Activity Of Hepatitis B Treatment Candidate - Benzinga
- 3 days ago - Precision BioSciences Announces Initial Safety and Antiviral Activity of PBGENE-HBV in the ELIMINATE-B Clinical Trial - Business Wire
- 24 days ago - Precision BioSciences Strengthens Senior Leadership Team to Drive Multiple In Vivo Gene Editing Programs - Business Wire
- 6 weeks ago - Precision BioSciences' Gene Editing Platform Has Differentiated Mechanism, And Is Potentially Competitive: Analyst - Benzinga
- 6 weeks ago - Precision BioSciences Announces Complete Clinical Response in First Infant Dosed by Partner iECURE in Ongoing Phase 1/2 Clinical Trial in Ornithine Transcarbamylase (OTC) Deficiency - Business Wire
- 6 weeks ago - iECURE Reports Complete Clinical Response in First Infant Dosed with its In Vivo Gene Editing Candidate ECUR-506 in an Ongoing Phase 1/2 Clinical Trial in Ornithine Transcarbamylase (OTC) Deficiency - Business Wire
- 2 months ago - Precision BioSciences Receives Approval in Hong Kong to Expand PBGENE-HBV Phase 1 ELIMINATE-B Trial for the Treatment of Chronic Hepatitis B - Business Wire
- 3 months ago - Precision BioSciences to Participate in Upcoming November Investor Conferences - Business Wire